Trial Profile
A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms IMPROVE
- Sponsors EMD Serono; Merck Serono
- 12 Oct 2018 Results of a post-hoc analysis assessing the dynamics of pseudoatrophy in RRMS patients treated with Interferon (IFN) beta-1a or placebo, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results of a post-hoc analysis assessing spatio-temporal characteristics of active MRI lesions, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.